Re: Expression of estrogen related proteins in hormone refractory prostate cancer: association with tumor progression. O. Celhay, M. Yacoub, J. Irani, B. Dore, O. Cussenot and G. Fromont. J Urol 2010; 184: 2172-2178. - Suppr | 超能文献

Re: Expression of estrogen related proteins in hormone refractory prostate cancer: association with tumor progression. O. Celhay, M. Yacoub, J. Irani, B. Dore, O. Cussenot and G. Fromont. J Urol 2010; 184: 2172-2178.

作者信息

Zhang Min

出版信息

J Urol. 2011 Aug;186(2):756. doi: 10.1016/j.juro.2011.03.160. Epub 2011 Jun 17.

DOI:10.1016/j.juro.2011.03.160

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Re: Expression of estrogen related proteins in hormone refractory prostate cancer: association with tumor progression. O. Celhay, M. Yacoub, J. Irani, B. Dore, O. Cussenot and G. Fromont. J Urol 2010; 184: 2172-2178.

J Urol. 2011 Aug;186(2):756. doi: 10.1016/j.juro.2011.03.160. Epub 2011 Jun 17.

2

Expression of estrogen related proteins in hormone refractory prostate cancer: association with tumor progression.

J Urol. 2010 Nov;184(5):2172-8. doi: 10.1016/j.juro.2010.06.089. Epub 2010 Sep 17.

3

Re: Olav Erich Yri, Trine Bjoro and Sophie D. Fossa. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. Eur urol 2006;49:54-8.

Eur Urol. 2007 Apr;51(4):1146. doi: 10.1016/j.eururo.2006.11.051. Epub 2006 Dec 4.

4

Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer.

J Pathol. 2005 Jun;206(2):205-13. doi: 10.1002/path.1767.

5

Re: Olav Erich Yri, Trine Bjoro and Sophie D. Fossa. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. Eur Urol 2006;49:54-58.

Eur Urol. 2007 Mar;51(3):864. doi: 10.1016/j.eururo.2006.06.030. Epub 2006 Jul 7.

6

Apoptosis and other mechanisms in androgen ablation treatment and androgen independent progression of prostate cancer: a review.

Cancer Detect Prev. 1998;22(5):476-84.

7

Re: Hendrik Isbarn, Jehonathan H. Pinthus, Leonard S. Marks, et al. Testosterone and prostate cancer: revisiting old paradigms. Eur Urol 2009;56:48-56.

Eur Urol. 2009 Nov;56(5):e23; author reply e24. doi: 10.1016/j.eururo.2009.06.033. Epub 2009 Jul 3.

8

Re: Russell Szmulewitz, Supriya Mohile, Edwin Posadas, et al. A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer. Eur Urol 2009;56:97-104.

Eur Urol. 2009 Nov;56(5):e36; author reply e37. doi: 10.1016/j.eururo.2009.07.052. Epub 2009 Aug 12.

9

Immunohistochemical expression of Hsp60 correlates with tumor progression and hormone resistance in prostate cancer.

Urology. 2010 Oct;76(4):1017.e1-6. doi: 10.1016/j.urology.2010.05.045. Epub 2010 Aug 12.

10

E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology.

Hum Pathol. 2001 Jul;32(7):690-7. doi: 10.1053/hupa.2001.25902.